`___________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`___________
`
`
`
`MYLAN PHARMACEUTICALS INC.,
`WOCKHARDT BIO AG,
`TEVA PHARMACEUTICALS USA, INC.,
`AUROBINDO PHARMA U.S.A., INC.,
`SUN PHARMACEUTICAL INDUSTRIES, LTD.,
`SUN PHARMA GLOBAL FZE and
`AMNEAL PHARMACEUTICALS LLC
`Petitioners,
`
`v.
`
`ASTRAZENECA AB,
`Patent Owner.
`
`
`
`Case: IPR2015-013401
`U.S. Patent No. RE 44,186
`____________________________________________
`
`ASTRAZENECA’S NOTICE AND SUBMISSION OF
`REPLACEMENT EXHIBIT NOS. 2220 AND 2220A
`
`
`
`
`1 Petitioner Wockhardt from IPR2016-01029, Petitioner Teva from IPR2016-
`01122, Petitioner Aurobindo from IPR2016-01117, and Petitioners Sun/ Amneal
`from IPR2016-01104 have been added as Petitioners to this proceeding.
`
`
`
`
`
`Pursuant to the Board’s email of December 21, 2016, Patent Owner
`
`Case No. IPR2015-01340
`Patent RE 44,186
`
`
`AstraZeneca AB hereby submits replacements for Exhibit 2220 and Exhibit
`
`2220A, which are the redacted and confidential copies, respectively, of the cross
`
`examination transcript of Dr. McDuff. Dr. McDuff’s errata sheet has been
`
`appended as pages 164 and 165 to both exhibits. No other changes have been made
`
`to either exhibit.
`
`Dated: December 22, 2016
`
`Respectfully submitted,
`
`By: /Anthony A. Hartmann /
`
`Anthony A. Hartmann, Reg. No. 43,662
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`(202) 408-4000
`
`Counsel for Patent Owner in
`IPR2015-01340
`
`1
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned certifies that copies of the foregoing ASTRAZENECA’S
`
`
`
`
`
`
`NOTICE AND SUBMISSION OF REPLACEMENT EXHIBIT NOS. 2220
`
`AND 2220A was served electronically via e-mail on December 22, 2016, in its
`
`entirety to the following:
`
`Counsel for Petitioner Mylan Pharmaceuticals Inc.:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Steven W. Parmelee
`sparmelee@wsgr.com
`
`Richard Torczon
`rtorczon@wsgr.com
`
`Jad A. Mills
`jmills@wsgr.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Douglas H. Carsten
`dcarsten@wsgr.com
`
`
`
`Counsel for Petitioner Wockhardt BIO AG.:
`
`
`
`
`
`Counsel for Petitioner Teva Pharmaceuticals U.S.A., Inc..:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Patrick Gallagher
`PCGallagher@duanemorris.com
`
`Gary Speier
`gspeier@carlsoncaspers.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Iain McIntyre
`imcintyre@carlsoncaspers.com
`
`
`
`
`
`
`
`
`
`
`
`Counsel for Petitioner Aurobindo Pharma U.S.A., Inc..:
`
`Case No. IPR2015-01340
`Patent RE 44,186
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Andrew Sommer
`ASommer@winston.com
`
`By: /Lauren K. Young/
`Lauren K. Young
`Litigation Legal Assistant
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, L.L.P.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Dated: December 22, 2016
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Sailesh K. Patel
`SPatel@schiffhardin.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`George Yu
`GYu@schiffhardin.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Counsel for Petitioners Sun/Amneal:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Samuel Park
`
`
`
`
`
`
`SPark@winston.com